XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Fair value measurement - Contingent Consideration (Details)
$ in Thousands, € in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jun. 30, 2022
EUR (€)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration, net of current portion $ 20,405 $ 29,542  
Contingent consideration 29,100    
Current portion of contingent consideration $ 8,681    
One hundred percent likelihood of AMT-260 advancing into clinical development      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Percentage of increase in Probability of Success 100.00%    
Change in fair value (presented within research and development expenses) $ 46,100    
Acquisition of Corlieve      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration, net of current portion $ 29,086 $ 29,542  
Percentage of increase in Probability of Success 55.00% 55.00%  
Change in fair value (presented within research and development expenses) $ 2,007    
Currency translation effects (2,463)    
Acquisition of Corlieve | Maximum      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration payable upon achievement of contractually defined milestones $ 186,900   € 178.8
Contingent consideration discount rate percentage 11.70% 11.90%  
Acquisition of Corlieve | Minimum      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration discount rate percentage 11.30% 10.90%